Interim report
Page 1
October 23, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited. (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/Madam, Sub: Unaudited Financial Results for the quarter and half-year ended September 30, 2026 Pursuant to Regulations 30 and 33 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regu lations, 2015 (“SEBI Listing Regulations”) and in furtherance to our letter dated September 22, 2026, we wish to inform you that the Board of Directors of the Company, at their meeting held today, i.e. October 23, 2026, inter alia considered and approved the following: a. Unaudited Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026, prepared in compliance with International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB); b. Press Release on Unaudited Financi al Results of the Company for the quarter and half-year ended September 30, 2026; c. Unaudited Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026, as per Indian Accounting Standards (Ind AS); d. Unaudited Standalone Financial Results of the Company for the quarter and half-year ended September 30, 2026, as per Indian Accounting Standards (Ind AS); and e. Limited Review Reports of the Statutory Auditors on the aforesaid Unaudited Standalone and Consolidated Financial Results as mentioned above. The Board Meeting commenced at 3:00 p.m. IST and concluded at 4:38 p.m. IST. This is for your information and records. Thanking you. Yours faithfully, For Dr. Reddy’s Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer & Head-CSR Encl: as above Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com
Page 36
•·· Dr. Reddy's ��• Notes: DR. REDDY'S LABORATORIES LIMITED I The above statement of unaudited standalone financial results of Dr. Reddy's Laboratories Limited ("the Company"), which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section I 33 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 23 October 2026 The Statutory Auditors have carried out a limited review on the unaudited standalone financial results and issued unmodified report thereon. 2 License and service income for the quarter ended 30 September 2026 includes: - Rs 529 million from the sale of the Company's territorial rights relating to Bendamustine HCL in the United States; and • Rs. 976 mil1ion towards achievement of certain milestones under various license agreements with a customer in Russia pertaining to biosimilars, These transactions pertain to the Company's Global Generics segment. 3 Revenue from sale of goods for the year ended 31 March 2026 includes the consequential impact of reduction in selling price of Lenalidomide product in the United States of USO 50 million. This transaction pertains to the Company's Global Generics segment 4 Certain batches ofSemaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient (AP!) used in the product Consequently, based on its best estimate, the Company has made a provision of Rs. 2,230 million towards inventory and Rs. 167 million towards other associated costs during the quarter ended 30 June 2026. 5 The Company has decided to discontinue certain of its R&D programs associated with Chimeric Antigen Receptor T-cell (CAR-T) therapy portfolio in light of current development status and recent clinical trial outcomes. Consequent to this decision, the Company has recognized a net Joss of Rs. I ,350 million during the quarter ended 31 March 2026 in the Company's Global Generics segment, comprising of: a. Impairment ofnon-current assets of Rs. I, 135 million (i.e .• towards Property, plant and equipment, Intangibles and Right of use assets), b. Research and development cost reimbursment to subsidiary of Rs. 198 million and c. Other development program related wind down cost of Rs, I 7 million, In August 2026, the company sold certain assets related to this CAR-T program and novated the related lease agreement to the acquirer resulting in impairment loss reversal of Rs. 137. 6 "Other income" for the year ended 31 March 2026 includes gain on sale of non-current assets, net of Rs. 1,890 million towards divestment of certain product related intangibles i.e., trademarks 7 During the year ended 31 March 2026 based on a final order received from the Federal Tax Service authority in respect of one of its foreign subsidiaries, based on its estimate. the Company had recorded a VAT provision of Rs. I ,&36 million under "Other expenses" including applicable interest and penalties and covering the periods both under audit as well as subsequent period up to 31 March 2026. The Company believes that the likelihood of any further liability that may arise on account of this field tax audit is not probable. This transaction pertains to the Company's Global Generics segment. 8 The Company considered the on-going uncertainties relating to geo-political conflicts (including in Russia. Ukraine and the Middle East) in assessing the recoverability of receivables, goodwill, intangible assets, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. Based on its judgments, estimates and assumptions, the Company expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions Place Hyderabad Date: 23 October 2026 By order of the Board For Dr. Reddy's Laboratories Limited G VP rasad Co-Chairman & Managing Director DIN: 00057433